May 19, 2017 11:05 AM EDTUpdated May 19, 08:46 PM
News Briefing

Astel­las, Pfiz­er scrap a PhI­II breast can­cer study us­ing Xtan­di; New $30M fund will back Is­raeli biotech star­tups

Shehla Shakoor

Managing Director

→ NanoS­tring Tech­nolo­gies notes in an SEC fil­ing that Astel­las and Pfiz­er have de­cid­ed to ter­mi­nate the late-stage EN­DEAR tri­al, which the com­pa­ny was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times